Lack of Association of First and Second-Line Medication Dosing and Progression to Refractory Status Epilepticus in Children

Abstract

Purpose: Evaluate the relationship between first and second-line medication dosing and progression to refractory status epilepticus (RSE) in children. Methods: This is a retrospective analysis of prospectively collected data from September 2014 to February 2020 of children with status epilepticus (SE) who received at least two antiseizure medications (ASMs). We evaluated the risk of developing RSE after receiving a low total benzodiazepine dose (lower than 100% of the minimum recommended dose for each benzodiazepine dose administered within 10 minutes) and a low first non-benzodiazepine ASM dose (lower than 100% of the minimum recommended dose of non-benzodiazepine ASM given as the first single-dose) using a logistic regression model, adjusting for confounders such as time to ASMs. The proportion of patients receiving low first non-benzodiazepine ASM doses was calculated and a logistic regression model was used to evaluate risk factors for low dosing of the first non-benzodiazepine ASM. Results: Among 320 children, 170 (53.1%) developed RSE, and 150 (46.9%) responded to the first non-benzodiazepine ASM dose (non-RSE). One hundred thirty-seven (42.8%) received a low total benzodiazepine dose, and 128 (40%) received a low first non-benzodiazepine ASM dose. The odds of developing RSE were not higher after a low total benzodiazepine dose (OR=0.76, 95%CI 0.47-1.23, p=0.27) or low first non-benzodiazepine ASM dose (OR=0.85, 95%CI 0.42-1.71, p=0.65). Receiving a low first non-benzodiazepine ASM dose was independently associated with having received a low total benzodiazepine dose (OR=1.65, 95%CI 1.01-2.70, p=0.04). Conclusion: For most patients, dosing variability in first and second-line medications for SE was not the sole clinical feature predicting progression to RSE in this cohort of benzodiazepine-resistant patients. Identification of additional modifiable clinical biomarkers that predict progression to RSE is needed. Though lower ASM doses did not predict RSE in this model, the administration of ASMs at doses likely to prevent RSE remains crucial in SE treatment.